Clinical and immunological analysis of letermovir for preventing cytomegalovirus infection in children after hematopoietic stem cell transplantation. (PubMed, Front Immunol) - May 8, 2026 - "Letermovir is safe and effective at reducing the risk of CMV infection in children after allo-HSCT, significantly delaying the onset of infection and shortening its duration. Although letermovir may impact early lymphocyte subset reconstitution, immune function can recover to pre-transplantation levels by 1 year post-transplantation."
Journal • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation • CD8
|
|
Bing Zhou; Hong Li; Hui Jiang; Jingbo Shao; Kai Chen; Na Zhang; Pan Fu; Qing Liu; Shumin Hou; Sijian Wang; Tianqiao Zhong; Yilin Wang
|